Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

Rhea-AI Summary

Relay Therapeutics (Nasdaq: RLAY) will report first quarter 2026 financial results and corporate highlights on Tuesday, May 5, 2026 after U.S. market close. The company is a clinical-stage small molecule precision medicine firm focused on oncology and genetic-disease therapies.

News Market Reaction – RLAY

+3.10%

+3.10% Session close to close

In the Apr 30 session, RLAY gained 3.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement schedules Relay Therapeutics’ Q1 2026 financial results and corporate highlights f...

Analysis

This announcement schedules Relay Therapeutics’ Q1 2026 financial results and corporate highlights for May 5, 2026 after market close. It follows a prior pattern where an earnings date notice precedes the detailed quarterly release. Investors monitoring the story may compare upcoming results with the last reported figures, including cash balance and net loss from 2025, and watch how new clinical and corporate updates interact with recent regulatory filings and trial data.

Key Figures

Earnings release date: May 5, 2026

1 metrics

Earnings release date May 5, 2026 Scheduled report of Q1 2026 financial results after U.S. market close

Previous Earnings date Reports

1 past event · Latest: Feb 19 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 19	Earnings date notice	Neutral	-1.8%	Set timing to release Q4 and full-year 2025 financial results and highlights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

For earnings date announcements, limited history shows a prior -1.81% move following a similar scheduling press release.

Recent Company History

Recent news has focused on zovegalisib clinical progress and financial updates. A prior earnings date notice on Feb 19, 2026 preceded the Q4 and full-year 2025 results released on Feb 26, 2026, which saw a 12.01% move after reporting $554.5M in cash and investments and a $276.5M net loss for 2025. Today’s announcement similarly sets expectations around timing for Q1 2026 results and corporate highlights.

Key Terms

precision medicine

1 terms

precision medicine medical

"a clinical-stage, small molecule precision medicine company developing"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report first quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Tuesday, May 5, 2026.

About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay Therapeutics’ Dynamo^® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company’s lead clinical asset, zovegalisib, is the first pan-mutant selective PI3Kα inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Kα-driven vascular anomalies. Relay Therapeutics’ pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit www.relaytx.com or follow us on LinkedIn.

Contact:
Pete Rahmer
prahmer@relaytx.com

Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com

FAQ

When will Relay Therapeutics (RLAY) release Q1 2026 results?

Relay Therapeutics will release Q1 2026 results after U.S. market close on May 5, 2026. According to Relay Therapeutics, the company plans to publish financial results and corporate highlights following the market close that day, with related investor materials typically posted online.

How can investors access Relay Therapeutics Q1 2026 results and highlights?

Investors can access the Q1 2026 results via the company investor website and SEC filings. According to Relay Therapeutics, financial results and corporate highlights will be posted online after the May 5, 2026 market close, and a press release will summarize key items.

Will Relay Therapeutics (RLAY) hold a conference call for Q1 2026 results?

The press release announces the timing of results but does not confirm a call. According to Relay Therapeutics, details about any conference call, webcast, or investor presentation will be provided alongside the May 5, 2026 financial release if scheduled.

What will Relay Therapeutics include in the May 5, 2026 corporate highlights?

Corporate highlights typically cover clinical updates, program progress, and corporate developments. According to Relay Therapeutics, the May 5, 2026 update will present first quarter financial results plus any notable clinical or corporate milestones achieved during the quarter.

What is Relay Therapeutics' business focus mentioned in the Q1 2026 announcement?

Relay Therapeutics is a clinical-stage small molecule precision medicine company focused on cancer and genetic disease therapies. According to Relay Therapeutics, its programs aim to develop small-molecule treatments addressing oncologic and genetic-disease targets.